Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1102

1.

Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators.

Tannenbaum S, Ross JS, Krumholz HM, Desai NR, Ritchie JD, Lehman R, Gamble GM, Bachand J, Schroter S, Groves T, Gross CP.

Ann Intern Med. 2018 Jul 17. doi: 10.7326/M18-0723. [Epub ahead of print] No abstract available.

PMID:
30014127
2.

Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors.

O'Connor JM, Seidl-Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP.

Oncologist. 2018 Jul 16. pii: theoncologist.2017-0673. doi: 10.1634/theoncologist.2017-0673. [Epub ahead of print]

PMID:
30012876
3.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy G, Ignatius Ou SH, Stephens PJ, McPherson J, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770-6. doi: 10.1016/j.jtho.2018.06.019. [Epub ahead of print]

PMID:
29981927
4.

Fusion Energy Output Greater than the Kinetic Energy of an Imploding Shell at the National Ignition Facility.

Le Pape S, Berzak Hopkins LF, Divol L, Pak A, Dewald EL, Bhandarkar S, Bennedetti LR, Bunn T, Biener J, Crippen J, Casey D, Edgell D, Fittinghoff DN, Gatu-Johnson M, Goyon C, Haan S, Hatarik R, Havre M, Ho DD, Izumi N, Jaquez J, Khan SF, Kyrala GA, Ma T, Mackinnon AJ, MacPhee AG, MacGowan BJ, Meezan NB, Milovich J, Millot M, Michel P, Nagel SR, Nikroo A, Patel P, Ralph J, Ross JS, Rice NG, Strozzi D, Stadermann M, Volegov P, Yeamans C, Weber C, Wild C, Callahan D, Hurricane OA.

Phys Rev Lett. 2018 Jun 15;120(24):245003. doi: 10.1103/PhysRevLett.120.245003.

PMID:
29956968
5.

The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data.

Wilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS.

NPJ Schizophr. 2018 Jun 27;4(1):14. doi: 10.1038/s41537-018-0055-7. Review.

6.

Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA.

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D.

J Mol Diagn. 2018 Jun 22. pii: S1525-1578(17)30527-5. doi: 10.1016/j.jmoldx.2018.05.004. [Epub ahead of print]

7.

Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.

Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, Ramkissoon SH.

Curr Treat Options Oncol. 2018 Jun 21;19(8):41. doi: 10.1007/s11864-018-0559-4. Review.

PMID:
29931654
8.

Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis.

Mangray S, Kelly DR, LeGuellec S, Fridman E, Aggarwal S, Shago M, Matoso A, Madison R, Pramanik S, Zhong S, Li R, Lombardo KA, Cramer S, Pressey J, Ross JS, Corona RJ, Bratslavsky G, Argani P, Coindre JM, Somers GR, Ali SM, Yakirevich E.

Am J Surg Pathol. 2018 Jun 12. doi: 10.1097/PAS.0000000000001098. [Epub ahead of print]

PMID:
29901569
9.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.

Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J.

Oncotarget. 2018 May 29;9(41):26417-26430. doi: 10.18632/oncotarget.25443. eCollection 2018 May 29.

10.

Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators.

Bates J, Parzynski CS, Dhruva SS, Coppi A, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Shaw RE, Warner F, Krumholz HM, Ross JS.

Pharmacoepidemiol Drug Saf. 2018 Jun 12. doi: 10.1002/pds.4565. [Epub ahead of print]

PMID:
29896873
11.

Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ignatius Ou SH.

J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30674-9. doi: 10.1016/j.jtho.2018.05.027. [Epub ahead of print]

12.

The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648.

PMID:
29871509
13.

The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657. No abstract available.

PMID:
29871507
14.

Fulfilling the Promise of Unique Device Identifiers.

Dhruva SS, Ross JS, Schulz WL, Krumholz HM.

Ann Intern Med. 2018 Jun 5. doi: 10.7326/M18-0526. [Epub ahead of print] No abstract available.

PMID:
29868760
15.

Network Optimization And The Continuity Of Physicians In Medicaid Managed Care.

Ndumele CD, Staiger B, Ross JS, Schlesinger MJ.

Health Aff (Millwood). 2018 Jun;37(6):929-935. doi: 10.1377/hlthaff.2017.1410.

PMID:
29863934
16.

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

O'Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP.

JAMA Oncol. 2018 May 10:e180798. doi: 10.1001/jamaoncol.2018.0798. [Epub ahead of print]

PMID:
29800974
17.

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS.

BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.

18.

Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.

Crossley JR, Tan TP, Smith KH, Ross JS, Merenstein DJ.

J Gen Intern Med. 2018 May 18. doi: 10.1007/s11606-018-4486-7. [Epub ahead of print] No abstract available.

PMID:
29777429
19.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
20.

Publication and Dissemination of Results in Clinical Trials of Neurology.

Sreekrishnan A, Mampre D, Ormseth C, Miyares L, Leasure A, Ross JS, Sheth KN.

JAMA Neurol. 2018 Jul 1;75(7):890-891. doi: 10.1001/jamaneurol.2018.0674. No abstract available.

PMID:
29710083
21.

The Impact of Off-Patent Drug Acquisitions on Prices.

Gupta R, Henkel A, Forman HP, Ross JS.

J Gen Intern Med. 2018 Jul;33(7):1007-1009. doi: 10.1007/s11606-018-4372-3. No abstract available.

PMID:
29687433
22.

Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens.

Severson EA, Riedlinger GM, Connelly CF, Vergilio JA, Goldfinger M, Ramkissoon S, Frampton GM, Ross JS, Fratella-Calabrese A, Gay L, Ali S, Miller V, Elvin J, Hadigol M, Hirshfield KM, Rodriguez-Rodriguez L, Ganesan S, Khiabanian H.

Blood. 2018 May 31;131(22):2501-2505. doi: 10.1182/blood-2018-03-840629. Epub 2018 Apr 20. No abstract available.

PMID:
29678827
23.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
24.

Older Drugs with Infantile Evidence: The Illustrative Example of Loop Diuretics.

Bikdeli B, Testani JM, Ross JS, Krumholz HM.

Eur Heart J Qual Care Clin Outcomes. 2018 Mar 29. doi: 10.1093/ehjqcco/qcy012. [Epub ahead of print] No abstract available.

PMID:
29617967
25.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW.

Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3.

PMID:
29615459
26.

National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults.

Rhee TG, Choi YC, Ouellet GM, Ross JS.

J Am Geriatr Soc. 2018 Mar 26. doi: 10.1111/jgs.15357. [Epub ahead of print]

PMID:
29582410
27.

Myeloid cell leukemia-1 protein expression and myeloid cell leukemia-1 gene amplification in non small cell lung cancer.

El Jabbour T, Dalvi SD, Kim S, Sheehan C, Ross JS.

Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):27-30. doi: 10.4103/IJPM.IJPM_731_16.

28.

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.

Wallach JD, Ciani O, Pease AM, Gonsalves GS, Krumholz HM, Taylor RS, Ross JS.

BMC Med. 2018 Mar 21;16(1):45. doi: 10.1186/s12916-018-1023-9.

29.

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.

Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20.

PMID:
29559559
30.

Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Gupta R, Bollyky TJ, Cohen M, Ross JS, Kesselheim AS.

BMJ. 2018 Mar 19;360:k831. doi: 10.1136/bmj.k831.

31.

Highly Resolved Measurements of a Developing Strong Collisional Plasma Shock.

Rinderknecht HG, Park HS, Ross JS, Amendt PA, Higginson DP, Wilks SC, Haberberger D, Katz J, Froula DH, Hoffman NM, Kagan G, Keenan BD, Vold EL.

Phys Rev Lett. 2018 Mar 2;120(9):095001. doi: 10.1103/PhysRevLett.120.095001.

PMID:
29547332
32.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

Suh JH, Schrock AB, Johnson A, Lipson D, Gay LM, Ramkissoon S, Vergilio JA, Elvin JA, Shakir A, Ruehlman P, Reckamp KL, Ou SI, Ross JS, Stephens PJ, Miller VA, Ali SM.

Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493. doi: 10.1634/theoncologist.2017-0493. [Epub ahead of print]

PMID:
29540602
33.

Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts.

Wallach JD, Ross JS.

JAMA. 2018 Feb 27;319(8):776-778. doi: 10.1001/jama.2017.21897. No abstract available.

PMID:
29486013
34.

Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.

Klara K, Kim J, Ross JS.

J Gen Intern Med. 2018 May;33(5):651-658. doi: 10.1007/s11606-017-4274-9. Epub 2018 Feb 26.

PMID:
29484575
35.

Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences.

Wallach JD, Egilman AC, Gopal AD, Swami N, Krumholz HM, Ross JS.

Res Integr Peer Rev. 2018 Jan 5;3:1. doi: 10.1186/s41073-017-0045-8. eCollection 2018.

36.

Laboratory evidence of dynamo amplification of magnetic fields in a turbulent plasma.

Tzeferacos P, Rigby A, Bott AFA, Bell AR, Bingham R, Casner A, Cattaneo F, Churazov EM, Emig J, Fiuza F, Forest CB, Foster J, Graziani C, Katz J, Koenig M, Li CK, Meinecke J, Petrasso R, Park HS, Remington BA, Ross JS, Ryu D, Ryutov D, White TG, Reville B, Miniati F, Schekochihin AA, Lamb DQ, Froula DH, Gregori G.

Nat Commun. 2018 Feb 9;9(1):591. doi: 10.1038/s41467-018-02953-2.

37.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. eCollection 2018 Feb.

38.

Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis.

Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P.

Clin Pharmacol Ther. 2018 Jan 29. doi: 10.1002/cpt.1038. [Epub ahead of print]

PMID:
29377075
39.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

PMID:
29373100
40.

Bringing Vioxx back to market.

Ross JS, Krumholz HM.

BMJ. 2018 Jan 25;360:k242. doi: 10.1136/bmj.k242. No abstract available.

PMID:
29371221
41.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.

PMID:
29370427
42.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

PMID:
29363525
43.

Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends.

Charalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A.

Med Care. 2018 Mar;56(3):260-265. doi: 10.1097/MLR.0000000000000867.

PMID:
29356721
44.

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Egilman AC, Wallach JD, Ross JS, Dhruva SS.

JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016. No abstract available.

PMID:
29340562
45.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.

46.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21. No abstract available.

PMID:
29325860
47.

Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes.

Lindenauer PK, Strait KM, Grady JN, Ngo CK, Parisi ML, Metersky M, Ross JS, Bernheim SM, Dorsey K.

Ann Am Thorac Soc. 2018 May;15(5):562-569. doi: 10.1513/AnnalsATS.201709-728OC.

PMID:
29298090
48.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.

Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W.

J Thorac Oncol. 2018 Jun;13(6):849-854. doi: 10.1016/j.jtho.2017.12.009. Epub 2017 Dec 27.

PMID:
29288764
49.

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.

Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P.

BMJ Open. 2017 Dec 21;7(12):e018587. doi: 10.1136/bmjopen-2017-018587.

50.

Defining Multiple Chronic Conditions for Quality Measurement.

Drye EE, Altaf FK, Lipska KJ, Spatz ES, Montague JA, Bao H, Parzynski CS, Ross JS, Bernheim SM, Krumholz HM, Lin Z.

Med Care. 2018 Feb;56(2):193-201. doi: 10.1097/MLR.0000000000000853.

PMID:
29271820

Supplemental Content

Support Center